At $28K a vial, Questcor's (QCOR) Acthar has propelled shares to huge gains. QCOR bought the drug for $100K in 2001, planning to produce it only to treat infantile spasms. But thanks to aggressive marketing, it's now being prescribed for MS, arthritis, and kidney disease. Aetna's (AET) decision to limit off-label treatments has hit shares, but it's not clear any viable alternatives are on the horizon. (NYT) [View news story]
Albert, the injections are for MS flare ups not to treat MS thus the timing of the injections is not regularly. Scott - QCOR has not been charging Medicare patients for Achtar. They have been refunding 100% of these prescriptions. They just recently announced that the Government had approved a much lower rebate and this hasn't gone through yet, but they should only have to refund 23% of these prescriptions in the future, instead of 100%. Also, the person who wrote this comment should edit their comment. None of these indications are off-label. That needs to be removed as it is completely untrue.
Congressional Budget Calls For Delay In Buying The Joint Strike Fighter; Sell Lockheed Martin [View article]
To be honest though, with the low volatility and everything else you can pick up a Jan 2013 put for that would have about an 80 -81$ break even point. You are risking less money and you cap your losses, whereas lets for some reason say that the government doesn't cut our something out of your control happens you only lose the 4$ /share. Then you are playing after the year and you don't have to worry about the dividend. In addition, you can take what would have been the rest of the position and put it somewhere with a decent yield, depending what kind of risk you want to take.
In regards to your comment on EK. I realize that by definition book value may equal -5 per share. However, the definition of book value does not give the proper value to there patent portfolio that was developed through internal R&D. Especially, the high-level of competition for the digital imaging patents. To put into perspective, the prior ruling in the ITC case ruled that their was some obvious level of infringement (although minor they specified) and have sent the case back to a lower court and changed the considerations that must be used. If you look at the cash flow value of these patents, it is pretty substantial. EK has shown that over the past few years. I don't pretend to give the value to the portfolio that the analyst do ($2-$3Billion), as I am not an expert in the field. However, even with a $1 Billion monetary value, which is what it is believed a RIMM and AAPL win in court could bring would be a little under $4/share in Free Cash Flow.
At $28K a vial, Questcor's (QCOR) Acthar has propelled shares to huge gains. QCOR bought the drug for $100K in 2001, planning to produce it only to treat infantile spasms. But thanks to aggressive marketing, it's now being prescribed for MS, arthritis, and kidney disease. Aetna's (AET) decision to limit off-label treatments has hit shares, but it's not clear any viable alternatives are on the horizon. (NYT) [View news story]
Questcor's 8-K Filing: Digging In The Details [View article]
Congressional Budget Calls For Delay In Buying The Joint Strike Fighter; Sell Lockheed Martin [View article]
Congressional Budget Calls For Delay In Buying The Joint Strike Fighter; Sell Lockheed Martin [View article]
4 Buy And 4 Sell Ideas By Cramer [View article]